Remember meForgot password?
    Log in with Twitter
Press Release

Liver Cancer Market Witnessing Innovative Therapies Focused on Re-Alignment of First-in-Class Molecular Targets with the Disease's Causes

The gap between the market and pipeline is huge. According to the latest data, the market at present contains 70 products, and majority of these products are generic formulations of chemotherapies, which are not frequently used for treating patients at the advanced-stage.

This press release was orginally distributed by SBWire

Albany, NY -- (SBWIRE) -- 09/03/2015 -- A new report on the liver cancer therapies market is now available on Market Research Reports Search Engine (MRRSE), the portal has announced. The report, titled 'Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation', by GBI Research, engages in a detailed analysis of the market and its therapies landscape. The report opens with a succinct prologue on liver cancer, its symptoms, pathophysiology, and treatment algorithms before delving on how the molecular landscape of the market is undergoing a change.

Browse Full Report with TOC @

It also pinpoints areas where maximum innovation is concentrated and offers insight into first-in-class therapies on the anvil (based on their development stage). Since patent and licensing trends are an inextricable aspect of the liver cancer market, these are discussed in detail as well.

According to analysts who have composed the report, the current liver cancer pipeline features about 238 products at the active stage of development. Of these, 47% are observed to be in the first-in-class therapies category. A sizeable portion of the pipeline is focused solely on innovative products – this figure is higher than the average recorded in the overall pharmaceutical industry and oncology.

Request a Sample Copy of the Report @

According to the report, the greatest trend in the liver cancer market currently is the calibration of first-in-class molecular targets with causes of liver cancer. As the industry increasingly aligns with a heightened understanding of abnormalities in signaling pathways and the reason for liver cancer, the change is visible in the pipeline.

Furthermore, the report states that a number of active deals in the liver cancer market have been reported in recent years. For a more inclusive study of the agreements and partnerships reported in the liver cancer market over the past few years, the report studies major licensing and co-development deals between 2006 and 2014.

A closer look at the market reveals that a vast contrast exists between the larger market and the lineup of therapies. Currently, the liver cancer market is composed of 70 products of which most are generic chemotherapy formulations that are not normally used. The report identifies Nexavar (sorafenib) as the current dominant therapeutic in the liver cancer market. On the other hand, an analysis of the pipeline reveals that a greater emphasis is laid on targeted therapies in the pipeline than in the current market. These facets of the market stand testimony to the fact that innovation and diversity are the tools that will help improve the status of the liver cancer market.

Browse Press Release @

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. Headquartered in New York, U.S., MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE's repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

For more information on this press release visit:

Media Relations Contact

Mr. Nachiket Ghumare
Assistant Manager
Telephone: 518-618-1030
Email: Click to Email Mr. Nachiket Ghumare

Latest News
Top News